September 2029: Trimetazidine, the Burden of Proof, and the Arithmetic of Tennis's Basement

My notebook keeps two kinds of dates. One kind is written in pencil, the ones I saw with my own eyes, sitting courtside, recorded in the margin of a score sheet. The other kind is written in ink, dates I never watched, but count anyway as a beat, because if you don't count the beat you cannot understand the tempo.

On Wednesday a third kind of date went into my ledger: September 2029.

By that month Parikshit Somani will be thirty. The ITIA's independent tribunal has ruled that he is barred from tennis for four years. Not only competing. Coaching is banned. So is attending a sanctioned event, even as a spectator.

The length of the ban is not what stops me. What stops me is the language. The tribunal called his explanation "scientifically implausible", "highly speculative" and "unconvincing".

Nowhere in the whole decision is there a stroke, a court, a scoreline. There are two numbers: 256 and 4.

Context: the player whose name never reached a scoreboard

Somani is a 26-year-old Indian player, primarily a doubles specialist. His career-high doubles ranking is No. 256, a long way below the main-tour cut. No singles ranking appears anywhere in the report. What is not stated is also information.

Last year, at a lower-tier event in Astana, Kazakhstan, his sample returned trimetazidine. Under the WADA Prohibited List it belongs to class S4, a metabolic modulator banned at all times, used as an anti-anginal heart medication, and the substance that has generated more contamination defences than any other in the history of anti-doping.

The ITIA, the International Tennis Integrity Agency, runs tennis's anti-doping and anti-corruption programmes on behalf of the ITF, the ATP, the WTA and the four Grand Slams. Its independent tribunal heard the case in August and announced its decision on Wednesday. The weeks between hearing and ruling are ordinary arbitration pace, not evidence of haste.

Strip the rule down and it reads like this: a prohibited substance in a sample is an Adverse Analytical Finding, and from there the burden belongs to the athlete. He must prove where the substance came from. Showing a plausible route is not enough; the source itself must be established. Claiming No Fault or Negligence raises that bar higher still. The final appeal route is the Court of Arbitration for Sport.

Somani's argument was contamination through food prepared by a family member. The tribunal did not accept it.

The core: the arithmetic breaks into several parts

I charted the 2026 final in pencil, and the margins knew the break points first. Numbers do the same work here: 256, 4, September 2029, and thirty. Put those four side by side and the internal arithmetic of the case surfaces, the part a headline never carries.

The first calculation is the ranking. During a suspension no ranking points can be earned or defended, and when the term ends the ranking has fully lapsed. The Protected Ranking mechanism that injured players rely on is generally unavailable for doping bans, because it was designed for injury layoffs. To return, he must start from zero: qualifying draws, small events, points rebuilt from nothing.

The second is the age curve. When a player's career-high doubles ranking at 26 is No. 256, the door to the top of the sport is already narrow. In September 2029 he will be thirty. The most fertile years of a playing life disappear inside the term.

The third has to be read the other way round. The competitive damage from the ban is smaller than the career damage. A man whose career-high doubles ranking is 256 is not a player knocked out of the elite, because he was never inside it. The loss sits elsewhere: age, experience and a name people trust have all been spent, and the ruling offers no route to recover them.

The fourth is the footprint of the sanction. It covers more than playing: coaching, administrative roles and even attendance at sanctioned events are barred. For a base-tier player, coaching or federation work is the natural alternative income. For four years that door is shut too. The suspension no longer ends at the baseline.

The fifth is the burden of proof. The real question in this case is not whether the substance entered his body. It is who has to prove where it came from. The answer is the athlete. Proving it requires equipment, a chain of documentation, a habit of keeping pharmacy receipts and lab-tested supplement records. Without those four things, there is no way to fight.

The sixth is the base-tier reality. A No. 256 doubles player travelling to a lower-tier event in Astana typically has no team doctor, no sports pharmacologist, no nutritionist. Food is handled by family, and the ruling exposes exactly the limits of that arrangement. The family kitchen and the household medicine box are the weakest link in base-tier anti-doping compliance. Where professional control never reaches, good intentions do not produce good paperwork.

The seventh is the supply of explanations. As the burden grows heavier, the easy explanations dry up. An athlete with no supply-chain records, no pharmacy receipts, no lab reports on supplements has almost no route other than "food prepared at home". That is precisely the defence tribunals trust least. This is not cruelty; it is the architecture of incentives. The system knows where it is easiest to fold, and it folds there. That is why the language sounds so hard.

The eighth is the timeline. The sample was collected in Astana, "last year". Then a provisional suspension, an August hearing, Wednesday's ruling, and an end date of September 2029. What is never made clear is the anchor date: whether the term is counted from sample collection or from the provisional suspension. It sounds small. It is not. A few months' drift is an entire pre-season. For people whose job is to keep records, that is a blank field.

The ninth is the precedent chain. Kamila Valieva's case involved the same substance and produced the same four-year outcome. Sun Yang's 2026 case involved the same substance but a different and heavily contested procedural line; reading factual similarity into it would be a mistake. The connection to Valieva is really about defence strategy, not about equivalent facts. Where the argument settles is this: same substance, same type of explanation, same result. Tribunals have grown steadily more sceptical of trimetazidine food-contamination defences, and that scepticism now runs as a line of precedent.

This is where my own ledger returns. The 2026 shutdown turned thirty-four years of archive dust into a living beat. That spring I rebuilt Bangladesh's Davis Cup record from scratch: from the 2026 debut through every tie, every rubber, every Sree-Amol Roy singles result. Forty-one ties, 178 rubbers, on one spreadsheet. It taught me a simple thing. For small tennis nations the real arena is the base tier, and the base tier is exactly what never gets fully recorded.

The same logic comes back around in Somani's case. India's tennis economy runs at the top; sponsorship follows television, and television turns to tennis when the name is big. A No. 256 player sits outside that mirror. For a small tennis nation the deficit stops being a deficit of strokes and becomes a deficit of structure. Blaming cricket by default is the easiest explanation on any South Asian sports desk, but the machinery is different: not every school has courts, sponsorship barely exists outside television, and the education and testing pipeline for base-tier medication never got funded. Meanwhile the academy announcements from former stars are mostly branding; nobody puts money into coach education.

Six days at the National Tennis Complex taught me that silence has a serve-and-volley rhythm. The 2026 Complex days are still in my spine, six days of watching rhythm become ritual. The same ritual surfaced in 2026 at the J30 events in Dhaka and Rajshahi, in Zarif Abrar's junior title, in BKSP's domestic dominance. Those juniors are still young. Some of them probably do not have a folder for lab reports.

And in the locker room, the quietest voice often carries the weight. At base tier that voice usually asks about medication. Or it does not ask, because nobody ever taught it what to ask.

The contrarian read

The outer reading is easy: a player was caught, he got four years, the system worked. Every word of that is true. But once that reading finishes, the question left behind is no longer simple.

Who fills the gap between the severity of the punishment and the difficulty of proving an explanation? For an athlete without the tools of proof, four years and two years are nearly the same thing, because returning at all becomes impossible. The harshness of a sanction is not set by the magnitude of the offence. It is set by what the athlete can put on the table in the place of proof. That is the least discussed truth of this case.

The second overreach lives in the language: is doping rising in tennis? Surveillance reach at lower-tier events like Astana and enforcement activity at the base tier are two different things. Treating one or two small cases as proof of an epidemic is headline arithmetic, not data.

The third overreach is the Valieva comparison. What the two cases share is defence strategy, and that overlap shows legal consistency. What Valieva's case had, and Somani's does not, is procedural storm and global visibility. The same outcome does not mean the same event; erase that distinction and a long legal process collapses into a three-word headline.

The fourth overreach concerns the tribunal's wording. "Scientifically implausible" sounds harsh, but harshness is how a system builds deterrence. The question that remains is who pays for that deterrence. For a top-tier athlete the cost is near zero: the team, the doctor, the lawyer are all in place. For the base tier, that cost is the whole sum.

The next beat: what to watch

First, the appeal paperwork. A filing at the Court of Arbitration for Sport would be the next step, though success on the same evidence looks unlikely, since the tribunal has already called the theory scientifically implausible. Second, the ITIA's published sanctions list, where the start date of the term should become clear; right now it is not. Third, the next trimetazidine rulings. If two or three in a row go the same way, the line hardens, and that becomes information worth having for every medication question of the coming season.

Then watch the juniors. There have been shifts in the Indian and Bangladeshi junior pools: the 2026 J30 events, Rajshahi, Zarif Abrar's title. Two questions sit there. One, how much their singles work is cutting. Two, whether anyone is teaching them the difference between a legal cough syrup and a prohibited molecule. The first question can be answered by watching matches. The second is answered only when somebody makes the mistake.

When the four years close in September 2029, whose notebook will still carry that date? The person who counted the term? Or the man himself, back at a qualifying draw, looking for a line on a sheet? That answer has not reached any scoreboard yet.